In 2013, San Antonio Breast Cancer Symposium (SABCS), Sherene Loi reported that TILs were associated with higher pCR rates after neoadjuvant trastuzumab and chemotherapy in early-stage HER2-positive breast cancer [27]. This evidence concerns the gene ERBB2 and breast carcinoma.